Combining anticoagulant and antiplatelet therapy after iliac vein stenting
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
This study is testing if using a combination of blood thinners and anti-clotting medication after iliac vein stenting can help people with deep vein thrombosis keep their veins open and healthy for a year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 172 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT04694248 on ClinicalTrials.gov |
What this trial studies
This study evaluates the efficacy and safety of a combination of anticoagulant and antiplatelet therapy on the patency of the iliac vein 12 months after stenting in patients with acute proximal deep vein thrombosis (DVT) and ipsilateral iliac vein stenosis. It is a single-arm, prospective, open-label, multicenter study conducted in Zhejiang Province, China, enrolling 172 subjects aged 18 and older. All participants will receive rivaroxaban and aspirin following their iliac vein stenting procedure, with follow-up assessments at 3, 6, and 12 months to document efficacy and safety endpoints. The study aims to provide insights into the optimal management of patients undergoing iliac vein stenting.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with acute proximal DVT and ipsilateral iliac vein stenosis who have undergone percutaneous mechanic thrombectomy and iliac vein stenting.
Not a fit: Patients with chronic DVT, isolated distal DVT, or significant renal impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve the long-term outcomes and vein patency for patients with iliac vein stenosis following stenting.
How similar studies have performed: While this approach is novel in this specific context, similar studies have shown promise in improving outcomes for patients with venous thromboembolic conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: IC1. Subjects who were diagnosed with deep venous thrombus (DVT) with ipsilateral iliac venous stenosis (\>50%). The ipsilateral iliac venous stenosis can be caused either by iliac vein compression (i.e. Cockett syndrome) or residue iliac venous thrombus after percutaneous mechanic thrombectomy. IC2. Subjects who accepted percutaneous mechanic thrombectomy (PMT) to decrease the burden of thrombus, with or without catheter directed thrombolysis (CDT). IC3. Subjects who accepted iliac venous stent(s) implantation during the perioperative period of PMT or CDT (≤30 days post PMT or CDT) . Exclusion Criteria: EC1. Subject has chronic DVT or the onset of DVT is longer than 3 weeks, or chronic DVT. EC2. Subject has isolated distal DVT, which does not affect ipsilateral femoral or iliac vein. EC3. Subject has glomerular filtration rate \< 60ml/min. EC4. Subject has ipsilateral varicose vein or suffers from ipsilateral venous insufficiency prior to the DVT. The manifestations of venous insufficiency include skin pigmentation, edema, lipodermatosclerosis and venous ulcer. EC5. Subject has acute arterial embolism on either side or suffers from known moderate or greater stenosis at abdominal aorta, ipsilateral iliac artery and ipsilateral lower extremity artery. EC6. Subject has known aneurysm(s) or current limiting dissection at abdominal aorta, ipsilateral iliac artery and ipsilateral lower extremity artery. EC7. Subject has contraindication to antiplatelet drugs or anticoagulants. EC8. Subject has systemic disease(s) that cannot be treated by current medicine. EC9. Subject has been taking anticoagulants or antiplatelet drugs for other diseases prior to the DVT. EC10. Subject less than 18 years old or rejected to join this study. EC11. Subject has myocardial infarction during the past 6 months. EC12. EC12. Subject who is at high bleeding risk\*. \* Subject who has at least one of the below conditions will be considered at high bleeding risk: Primary history of intracerebral haemorrhage or ischemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, or renal failure requiring dialysis or with eGFR \<15ml/min/1.73 m2.
Where this trial is running
Hangzhou, Zhejiang
- The First Affliated Hospital, Zhejiang University, School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Hongkun Zhang, M.D. — First Affiliated Hospital of Zhejiang University
- Study coordinator: Hongkun Zhang, M.D.
- Email: 1198050@zju.edu.cn
- Phone: 0571-87236745
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.